This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Von Gierke disease / Glycogen storage disease type I폰기에르케병 (글리코젠축적병 1형)

Contents and key points
ItemDetails
A. Classification codesICD-10: E74.0 (glycogen storage disease) | Special Copayment Reduction: V117 (rare disease)
B. SynonymsVon Gierke disease, glycogen storage disease type Ia (GSD Ia, G6Pase deficiency), glycogen storage disease type Ib (GSD Ib, G6P translocase deficiency), glycogen storage disease type I, glucose-6-phosphatase deficiency, G6PC deficiency, SLC37A4 deficiency (type Ib)
C. Adult onsetPossibility of first manifestation in adulthood: low — Most are diagnosed in infancy (3-6 months of age) with abdominal distension, hypoglycemia, and lactic acidosis. However, cases discovered incidentally in adulthood, or diagnosed from hepatic adenoma complications, in carriers of mild variants or in patients who had no opportunity for diagnosis have been rarely reported.
1. History1929 first description by von Gierke → 1952 G6Pase deficiency confirmed by the Coris → 1978 discovery of G6PT → 1993 cloning of the G6PC gene → 1998 cloning of SLC37A4 → after 2002 optimization of cornstarch therapy → 2020s entry of mRNA/gene therapy research.
2. CausesGSD Ia: glucose-6-phosphatase (G6Pase) deficiency due to mutations of the G6PC gene. GSD Ib: G6P translocase (G6PT) deficiency + neutrophil dysfunction due to mutations of the SLC37A4 gene. Autosomal recessive inheritance.
3. GeneticsG6PC: 17q21.31, 5 exons. SLC37A4: 11q23.3. Frequent variants in Korea and Asia: G6PC c.648G>T (p.Leu216=, exon 5 splicing), etc. Frequent variants of GSD Ib in Korea: SLC37A4 c.1042_1043del, etc. Autosomal recessive.
4. General epidemiologyOverall GSD I prevalence about 1 in 100,000. GSD Ia about 80%, GSD Ib about 20%. Reported worldwide, with GSD Ia occurring frequently in Ashkenazi Jews (1 in 20,000). The number of GSD I patients in Korea is estimated at several dozen.
5. PathophysiologyG6Pase or G6PT deficiency → blockade of the final step of glycogenolysis and gluconeogenesis in the liver, kidney, and intestine → fasting hypoglycemia + accumulation of lactate, triglycerides, and uric acid. In GSD Ib, impaired G6P translocation additionally reduces the neutrophil oxidative burst function.
6. SymptomsFasting hypoglycemia (seizures, decreased consciousness), abdominal distension (hepatomegaly), growth retardation, doll-like face, and in GSD Ib recurrent infections, oral ulcers, and symptoms resembling inflammatory bowel disease.
7. SignsHepatomegaly (sometimes massive hepatomegaly), nephromegaly, abdominal distension, signs of hypoglycemia, blood tests: hypoglycemia, lactic acidosis, hyperuricemia, hyperlipidemia (especially high triglycerides). GSD Ib: neutropenia.
8. ScreeningFasting metabolic profile (glucose, lactate, uric acid, triglycerides, ketone bodies), newborn metabolic screening (when blood glucose is abnormal), genetic testing of newborns with a family history. Direct inclusion of GSD I in newborn screening in Korea is not yet standard.
9. DiagnosisBiochemistry: fasting hypoglycemia + hyperlactatemia + hyperuricemia + hypertriglyceridemia. Measurement of G6Pase activity in liver biopsy (historical standard). Current standard: G6PC/SLC37A4 gene analysis. Glucagon stimulation test (no glycemic response, lactate rises). Liver ultrasound and MRI (evaluation of fatty liver and adenoma).
10. TreatmentDietary therapy: maintenance of blood glucose by regular administration of uncooked cornstarch (UCCS). Nocturnal gastric tube feeding supplementation. Allopurinol (hyperuricemia). ACE inhibitors (renal protection). GSD Ib: granulocyte colony-stimulating factor (G-CSF). Monitoring and resection of hepatic adenoma. Gene therapy clinical trials are under way.
11. PrognosisWith adherence to dietary therapy, growth and development can normalize. Long-term complications: hepatic adenoma (risk of malignant transformation), decreased renal function (glomerulosclerosis), osteoporosis, gout. GSD Ib: risk of myelodysplasia reported with long-term G-CSF use.
12. PreventionGenetic counseling and family genetic testing. Education on hypoglycemia emergency protocols. Strict limitation of fasting time. Regular liver ultrasound and renal function monitoring. Restriction of a high-purine diet.
13. ReferencesBhattacharya K et al. J Inherit Metab Dis 2020 and 9 other papers

1. History

The history of von Gierke disease began in 1929, when the German pathologist Edgar von Gierke first described two pediatric cases with excessive glycogen accumulation in the liver and kidney. Histologically, he observed abundant glycogen in hepatocytes and proximal tubular cells and named it 'hepatonephrogenous glycogenosis'. At that time the mechanism was entirely unknown, but severe abdominal distension and recurrent hypoglycemia were described strikingly as clinical features.

In 1952, Gerty Cori and Carl Cori measured glucose-6-phosphatase (G6Pase) activity in liver homogenates and demonstrated that this enzyme is deficient in patients with von Gierke disease. The Coris proposed a system for classifying glycogen storage diseases by type of enzyme deficiency and named von Gierke disease GSD type I, and this work was an extension of the Cori cycle research that underlay the 1947 Nobel Prize in Physiology or Medicine.

In the 1970s, it became known that, separate from GSD Ia, there is a variant that shows an identical clinical phenotype despite having G6Pase enzyme activity. In 1978, Sezari et al. defined this as impaired G6P transport across the microsomal membrane, and this variant was subsequently named GSD Ib. In 1993, Lei et al. cloned the G6PC gene on chromosome 17q21, and in 1998 Chou et al. cloned SLC37A4, the causative gene of GSD Ib, on 11q23.3.

The biggest turning point in the history of treatment was the 1979 report by Greene et al. that uncooked cornstarch (UCCS), which is digested slowly in the gastrointestinal tract and releases glucose gradually, is effective for maintaining blood glucose. UCCS therapy subsequently became the standard of GSD I management and played a key role in preventing nocturnal hypoglycemia. In the 2000s, extended-release cornstarch (Glycosade) was developed, making it possible to maintain blood glucose for longer periods. Since the 2010s, AAV-based gene therapy research has succeeded in animal models, and in the 2020s human clinical trials have entered, exploring the possibility of a fundamental cure.

Neutropenia and neutrophil dysfunction in GSD Ib were first systematically described by Cogan et al. in 1984, and G-CSF treatment was subsequently shown to be effective in correcting this complication. A distinctive clinical picture in which gastrointestinal symptoms resembling inflammatory bowel disease occur in GSD Ib patients was also revealed. In 2019, reports that SGLT2 inhibitors such as empagliflozin improve neutropenia in GSD Ib drew attention, and this is drawing attention as a new mechanism that bypasses G6PT function.

In Korea, GSD I cases have been reported from pediatric and metabolic disease specialty institutions since the 1980s-90s, and as genetic testing-based diagnosis became established, it was confirmed that specific G6PC and SLC37A4 variants are frequent in Koreans. Currently, under the Special Copayment Reduction V117 registration system, copayment reduction is provided along with multidisciplinary management centered on specialized metabolic disease centers.


2. Causes

Von Gierke disease (GSD type I) is an autosomal recessive genetic disease caused by a defect in the glucose-6-phosphatase (G6Pase) system responsible for the final step of glycogen breakdown and gluconeogenesis in the liver, kidney, and intestinal mucosa. It is broadly divided into two subtypes.

GSD type Ia: Owing to pathogenic variants of the G6PC gene (chromosome 17q21.31), the G6Pase catalytic subunit (G6PC), located in the lumen of the endoplasmic reticulum, is deficient or loses function. G6PC is an enzyme that hydrolyzes glucose-6-phosphate (G6P) into free glucose and inorganic phosphate, and this reaction constitutes the final step of glycogenolysis and gluconeogenesis in the liver. In G6PC deficiency, G6P cannot be broken down and accumulates in the liver and kidney, and free glucose cannot be released into the blood, causing fasting hypoglycemia. At the same time, the accumulated G6P is diverted to glycogen synthesis, worsening hepatic and renal glycogen accumulation. The G6PC gene consists of 5 exons and encodes a 357-amino-acid endoplasmic reticulum transmembrane protein. More than 100 pathogenic variants have been reported worldwide; the R83C (c.247C>T) variant is reported at relatively high frequency in Ashkenazi Jews, and splicing variants such as c.648G>T in East Asians, including Koreans.

GSD type Ib: Owing to pathogenic variants of the SLC37A4 gene (chromosome 11q23.3), G6P translocase (glucose-6-phosphate translocase, G6PT), which transports G6P into the lumen across the endoplasmic reticulum membrane, is deficient. The G6Pase enzyme itself is normal, but the substrate G6P is not supplied to the endoplasmic reticulum lumen, so the same metabolic disorder as in type Ia occurs. In addition, in GSD type Ib, impaired intracellular glucose metabolism due to G6PT deficiency also occurs in neutrophils and monocytes, causing neutrophil dysfunction (decreased oxidative burst, impaired chemotaxis) and neutropenia. SLC37A4 encodes a transmembrane protein consisting of 10 exons, and in GSD type Ib in particular c.1042_1043del (p.Trp348Leufs), G339C, and other missense variants are reported.

Both subtypes are inherited as autosomal recessive; when each parent is an asymptomatic carrier with one pathogenic variant, there is a 25% probability that a child will be affected. De novo mutations are rare, and in most cases a variant within the family is passed on.


3. Genetics

The G6PC gene is located on chromosome 17q21.31, with a total size of about 12.5 kb and 5 exons. The translation product is a 357-amino-acid endoplasmic reticulum transmembrane protein, forming 9 transmembrane domains with the active site in the endoplasmic reticulum lumen. The catalytic residues are His119 and Arg83, and variants at these positions (R83C, H119L, etc.) are high-frequency pathogenic variants. More than 100 pathogenic variants of G6PC have been identified worldwide, covering missense, nonsense, splicing, and small deletion/insertion variants. In Ashkenazi Jews, a founder effect is prominent, with the two variants R83C (c.247C>T) and Q347X (c.1039C>T) accounting for about 70-80% of the total. In East Asia (Korea, China, Japan), c.648G>T (exon 5, a cryptic splicing variant causing loss of protein function) and p.Leu216= are known to be frequent.

The SLC37A4 gene is located on chromosome 11q23.3 and encodes 10 exons and an mRNA of about 4.3 kb. The translation product is a 429-amino-acid endoplasmic reticulum transmembrane protein with 10 transmembrane domains. It is responsible for transporting G6P across the endoplasmic reticulum membrane and is also expressed in neutrophils and monocytes, where it is involved in glucose metabolism of these cells. Pathogenic variants of GSD type Ib reported include c.1042_1043del (p.Trp348Leufs*24), c.1015G>A (p.Gly339Arg), and other missense and nonsense variants. Founder variants within specific ethnic groups have been reported but are more diverse than in GSD Ia.

Both genes follow an autosomal recessive mode of inheritance, so a patient develops the disease only when variants are present in both alleles (homozygous or compound heterozygous), having inherited one pathogenic variant from each parent. A carrier has a normal phenotype but has one variant, and of children born to two carrier parents, 25% are patients, 50% are carriers, and 25% are normal. Prenatal diagnosis is possible through chorionic villus sampling or amniocentesis, and when the familial variant has been identified, direct genetic analysis is the standard.

Phenotype-genotype correlation: In GSD Ia, loss-of-function variants such as nonsense variants and deletions tend to completely abolish enzyme activity and cause severe hypoglycemia and marked metabolic abnormalities, while some missense variants (especially R83H) retain partial residual G6Pase activity and may show a relatively mild phenotype. In GSD Ib, the homozygous c.1042_1043del variant is associated with severe neutropenia and symptoms resembling inflammatory bowel disease. However, there is considerable phenotypic variation even within the same genotype, so it is difficult to fully predict clinical severity from genotype alone.

Next-generation sequencing (NGS)-based multigene panels or whole exome sequencing (WES) are now the diagnostic standard, and genetic analysis is recommended first, especially when biochemical findings are atypical or liver biopsy is to be avoided. Comparative interpretation with variant databases (ClinVar, HGMD) and concurrent functional testing are essential for determining variant pathogenicity.


4. General epidemiology

Von Gierke disease (GSD type I) is the most frequent subtype among all glycogen storage diseases, and its worldwide prevalence is estimated at about 1 in 100,000 births. GSD type Ia (G6Pase deficiency) accounts for about 80% of all GSD I, and GSD type Ib (G6PT deficiency) for the remaining about 20%. There is no difference in incidence by sex, and owing to autosomal recessive inheritance, men and women are affected with equal frequency.

A founder effect in specific ethnic groups is prominent. In Ashkenazi Jews, the frequency of GSD Ia is about 1 in 20,000, about 5 times higher than in the general population, and the two variants R83C and Q347X account for about 70-80% of patients in that group. This reflects the effect of inbreeding within a historically closed population. Specific founder variants have also been identified in East Asia, including Japan and Korea, but the difference in frequency is not as marked as in the West.

Precise prevalence data within Korea are limited, but according to Health Insurance Review & Assessment Service and rare disease registry data, registered GSD I (E74.0) patients are estimated at several dozen. In Korea, diagnosis and management are centered on pediatric and adolescent endocrine and metabolic specialty clinics, and medical cost support is received through Special Copayment Reduction (V117) registration. Age at diagnosis is mostly infancy (3-6 months of age), and many are first discovered by hypoglycemic seizures after fasting or upper abdominal distension (hepatomegaly).

In the case of GSD Ib, diagnosis may occur at an earlier age or by more varied routes owing to recurrent infections due to neutropenia, oral ulcers, and symptoms resembling inflammatory bowel disease. Worldwide, because GSD I is not included in newborn screening, delayed diagnosis is still common in terms of access to diagnosis, and in particular cases diagnosed posthumously or after intensive care unit admission for severe neonatal hypoglycemia or lactic acidosis have been reported. Regular fasting metabolic testing and efforts to systematically identify the cause of neonatal and infant hypoglycemia are important for early diagnosis.

GSD I is a distinct disease, but it has clinical similarities to other glycogen storage diseases, so differential diagnosis from Pompe disease (GSD II), Cori disease (GSD III), and phosphorylase deficiency (GSD VI) is needed. An important distinguishing point from other GSDs is that in GSD I ketosis is absent or mild while lactic acidosis is pronounced.


5. Pathophysiology

The core pathophysiology of von Gierke disease is the inability to release glucose due to functional defects in the G6Pase system in the liver and kidney, and the resulting combined metabolic abnormalities. Normally the liver generates G6P through the two pathways of glycogenolysis and gluconeogenesis, and G6Pase converts it into free glucose and releases it into the blood, maintaining fasting blood glucose. When G6Pase or G6PT is deficient in GSD I, G6P cannot be converted into free glucose and accumulates in the endoplasmic reticulum within hepatocytes.

Fasting hypoglycemia: Because glucose cannot be generated from G6P, blood glucose falls rapidly within 2-3 hours after a meal. The fall in blood glucose triggers glucagon secretion and sympathetic activation, but glycogenolysis in response to glucagon also does not translate into a rise in blood glucose without G6Pase, so the compensatory mechanism is nullified. This is the mechanism of the characteristic 'glucagon-unresponsive hypoglycemia'.

Lactic acidosis: Accumulated G6P is converted to pyruvate through glycolysis, and excessive pyruvate production causes lactic acid accumulation. In addition, precursors of gluconeogenesis (lactate, alanine, pyruvate, etc.) are blocked at steps after G6P, so lactate accumulates in the circulation. Chronic lactic acidosis causes growth impairment and bone mineral loss.

Hyperuricemia: Two mechanisms act in combination. ① Excess G6P activates the pentose phosphate pathway → increased ribose-5-phosphate → promotion of purine synthesis → increased uric acid production. ② Chronic lactic acidosis suppresses competitive renal secretion of organic acids and uric acid → decreased uric acid excretion. This is why gouty arthritis occurs early (in the teens) in untreated patients.

Hyperlipidemia (especially hypertriglyceridemia): Decreased insulin (relative hypoinsulinemia) + reduced signals inhibiting fatty acid oxidation → increased fatty acid synthesis and VLDL secretion in the liver. Decreased expression of the low-density lipoprotein receptor (LDL-R) also contributes. Hypertriglyceridemia increases the risk of pancreatitis and in the long term is a risk factor for atherosclerosis.

Hepatic and renal glycogen accumulation: Unprocessed G6P is continuously synthesized into glycogen and accumulates in hepatocytes and renal proximal tubular cells. The resulting cell swelling is the cause of hepatomegaly and nephromegaly. In the long term, persistent hepatocyte injury and regeneration and fat deposition (fatty liver) occur, increasing the risk of hepatic fibrosis and hepatocellular adenoma (HCA). Some HCAs can undergo malignant transformation (hepatocellular carcinoma).

Additional mechanism in GSD type Ib — neutrophil dysfunction: G6PT is also required in neutrophils and monocytes, where it supplies glucose from the endoplasmic reticulum to carry out the oxidative burst through NADPH oxidase. Neutrophils deficient in G6PT have reduced oxidative burst function and impaired bacterial killing, and at the same time their lifespan is shortened by abnormal cell survival signals, causing neutropenia. For this reason, GSD Ib patients are vulnerable to recurrent bacterial infections, oral ulcers, and perianal ulcers, and a characteristic Crohn's disease-like inflammatory bowel disease phenotype appears. Recent studies have reported that intracellular accumulation of 1,5-anhydroglucitol in neutrophils can be used as a marker that serves as a surrogate for G6PT function.


6. Symptoms

The clinical symptoms of von Gierke disease can begin immediately after birth, and in most cases become evident within 3-6 months of age. If untreated, severe acute metabolic crises occur due to fasting hypoglycemia and lactic acidosis, and in the long term multiple-organ complications develop owing to the combined metabolic abnormalities.

Symptoms of acute hypoglycemia: Within 2-4 hours after a meal, blood glucose falls rapidly, causing hypoglycemic symptoms such as sweating, pallor, anxiety, muscle tremor, seizures, and decreased consciousness. In the neonatal period, a hypoglycemic seizure may be the first presenting symptom when feeding intervals lengthen or feeding is poor. If severe hypoglycemia recurs, there is a risk of neurological damage.

Abdominal symptoms: Hepatomegaly is marked, and the abdomen is markedly distended from infancy. The liver can enlarge so that the liver edge extends 6-10 cm or more below the umbilicus, with a smooth surface and relatively soft texture. Splenomegaly is absent or mild in most cases (if splenomegaly is prominent, consider other diagnoses such as GSD III). Nephromegaly also accompanies but is often not clearly detectable on physical examination. Along with abdominal distension, anorexia, nausea, and early satiety may appear.

Growth impairment: In untreated patients, growth retardation occurs owing to chronic hypoglycemia, chronic lactic acidosis, and malnutrition. The characteristic 'doll-like face' has a plump appearance owing to fat deposition in the cheeks, while the limbs are relatively thin with reduced muscle mass. This reflects abnormal subcutaneous fat distribution due to hyperlipidemia and muscle loss due to chronic metabolic abnormalities.

Epistaxis and bleeding tendency: Owing to platelet dysfunction (presumed impaired platelet-endothelial cell interaction) along with hypertriglyceridemia, there is a tendency for frequent epistaxis or prolonged bleeding. In preoperative coagulation tests, abnormal platelet aggregation function is sometimes found.

Uric acid-related symptoms: In childhood hyperuricemia is often asymptomatic, but in untreated patients after adolescence gouty arthritis may occur. Uric acid nephrolithiasis due to uric acid overload in the kidney may also occur.

Additional symptoms of GSD Ib: Recurrent bacterial infections (skin, ear canal, urinary tract, respiratory tract), severe oral ulcers and gingival disease, perianal abscesses and fistulas, and Crohn's disease-like gastrointestinal symptoms such as abdominal pain, diarrhea, bloody stool, and weight loss are characteristic. In some patients, gastrointestinal symptoms appear before hypoglycemia, which delays diagnosis.


7. Signs

The most prominent finding on physical examination is marked hepatomegaly. The lower liver edge is palpable 6-12 cm below the umbilicus, with a smooth, non-firm texture. The spleen is mostly normal or mildly enlarged. Along with overall abdominal distension, decreased rectus abdominis muscle tone may be observed. In infants, abdominal distension may form a 'barrel abdomen' appearance.

Growth and body habitus signs: Height and weight are in the lower percentiles of the growth curve for age, and a 'doll-like face' — plump cheeks, a flat and low nasal bridge, and relatively short stature and limbs — is characteristic. Subcutaneous fat is relatively abundant in the cheeks, neck, and trunk, and the limbs are thin.

Cutaneous xanthoma: When severe hypertriglyceridemia persists, eruptive xanthomas may appear on the elbows, knees, buttocks, etc.

Laboratory findings: Fasting hypoglycemia (blood glucose < 50 mg/dL, < 30 mg/dL in severe cases), elevated serum lactate (5-15 mmol/L or higher versus normal 1-2 mmol/L), elevated serum uric acid, elevated serum triglycerides (500-4,000 mg/dL), mildly elevated serum cholesterol, elevated AST/ALT. Ketone bodies are normal or mildly elevated (the absence of marked ketonemia is a clue for differentiation from GSD III, etc.). No glycemic response and a rise in lactate after glucagon stimulation is a highly characteristic biochemical response in GSD I. Blood acylcarnitine profile and urine organic acid analysis are used for differentiation from other organic acidemias.

Liver ultrasound and MRI: The liver shows increased echogenicity (fat deposition) and markedly increased size. After adulthood, hepatocellular adenoma (HCA) may be observed as single or multiple lesions, and it is important to evaluate on MRI a size of 5 cm or more, hemorrhage within the HCA, and signs of HCA-to-HCC transformation (dysplasia, irregular capsule). MRI is the most sensitive for analyzing the composition of HCA (fat content, hemorrhage, malignant transformation).

Additional signs in GSD Ib: Oral ulcers, gingival hypertrophy and bleeding, perianal ulcers or fistulas, abdominal tenderness (resembling inflammatory bowel disease), and decreased absolute neutrophil count on peripheral blood testing (ANC < 1,500/μL, < 500/μL in severe cases) are characteristic. Bone marrow examination may show maturation arrest of the myeloid lineage.


8. Screening

Standardized universal newborn screening for von Gierke disease is not currently performed in Korea or abroad. GSD I is not included in tandem mass spectrometry-based newborn screening panels, and it is difficult to screen using dried blood spots alone without enzyme activity measurement or direct genetic analysis. Therefore, early clinical diagnosis through clinical symptoms and biochemical abnormalities is the realistic screening strategy.

Clinical early screening indicators: GSD I should be strongly suspected when the following clinical and biochemical patterns are identified in infancy. ① Blood glucose < 50 mg/dL after fasting or a prolonged feeding interval (especially non-ketotic hypoglycemia with absent or low ketone bodies). ② Significantly elevated serum lactate (more than twice normal). ③ Hyperuricemia (above the age reference value). ④ Hypertriglyceridemia. ⑤ Hepatomegaly (confirmed by ultrasound). The combination of these 5 findings is highly specific for GSD I. In particular, the triad of 'hypoglycemia without ketosis + lactic acidosis + hepatomegaly' is the key screening clue for GSD I.

Metabolic challenge test (fasting provocation test): While performing a systematic supervised fast, blood glucose, lactate, ketone bodies, free fatty acids, insulin, growth hormone, and cortisol are measured serially to determine the hypoglycemia-provoking pattern. In GSD I, the pattern is characterized by a rapid fall in blood glucose within 2-4 hours of fasting, a paradoxical rise in lactate, and no rise in ketone bodies. This test must be performed safely at a specialized center, and caution is needed when severe hypoglycemia is expected.

Glucagon stimulation test: In the postprandial (non-fasting) state, glucagon 1 mg is injected intramuscularly and the change in blood glucose is measured within 30 minutes. In normal individuals blood glucose rises significantly (≥ 30 mg/dL), but in GSD I there is no or minimal rise in blood glucose, and a non-response pattern appears in which lactate rises instead. This test provides important biochemical evidence for screening of GSD I.

Family history-based screening: For families who have previously had a child born with GSD I, prenatal genetic diagnosis (chorionic villus sampling or amniocentesis) is possible in the next pregnancy. When the familial variant has been identified, preimplantation genetic testing (PGT) is also possible. Early genetic testing in the neonatal period is recommended when a sibling or cousin has GSD I.


9. Diagnosis

Diagnosis of von Gierke disease proceeds through the steps of clinical-biochemical findings, enzyme activity measurement, and molecular genetic confirmation. The current standard is confirmation of pathogenic variants of the G6PC or SLC37A4 gene, and in most cases a definitive diagnosis is possible by genetic analysis alone without liver biopsy.

Biochemical diagnosis: GSD I is strongly suggested when the following combination of findings is identified on a standard fasting test (or fasting provocation test). ① Decreased blood glucose (< 50 mg/dL, < 30 mg/dL in severe cases). ② Elevated serum lactate (5-20 mmol/L). ③ Elevated serum uric acid. ④ Markedly elevated serum triglycerides (500-4,000 mg/dL). ⑤ Mildly elevated serum cholesterol. ⑥ Ketone bodies normal or mildly elevated (non-ketotic hypoglycemia). ⑦ No glycemic response and a rise in lactate to glucagon stimulation. AST and ALT are mildly to moderately elevated, and serum phosphate is normal (no hypophosphatemia), and serum calcium and magnesium are mostly normal. Urinalysis may show excessive uric acid excretion and proteinuria (in advanced renal complications).

Molecular genetic confirmation: Targeted variant analysis or full gene sequencing (NGS-based panel or WES) of G6PC (suspected GSD Ia) or SLC37A4 (suspected GSD Ib, especially with neutropenia) is performed. The diagnosis is confirmed when pathogenic variants are identified in both alleles. When a variant is identified in only a single allele, gene copy number variation (CNV) analysis or mRNA analysis is added. The sensitivity of genetic analysis is about 97-98% in GSD Ia and similarly high in GSD Ib, so we have entered an era in which molecular confirmation is possible without enzyme testing.

Enzyme activity testing: The historical standard was measurement of G6Pase activity in fresh liver biopsy tissue. In GSD Ia, loss of G6Pase activity (below 10% of normal) is found, and in GSD Ib, impaired G6P transport function is found using isolated microsomes. However, fresh tissue is required and testing institutions are limited, so it is currently being replaced by genetic analysis. It is used selectively only when molecular confirmation is not possible.

Liver ultrasound and MRI: Liver size, fat deposition, and the presence of adenoma are evaluated at diagnosis and in follow-up. Hepatic adenomas develop after adolescence, so periodic imaging follow-up is essential. MRI is the most useful for evaluating hemorrhage and malignant transformation of HCA. Increased kidney size (nephromegaly) and nephrolithiasis are also checked by ultrasound.

Additional diagnosis in GSD Ib: Confirmed through regular measurement of the absolute neutrophil count (ANC), neutrophil function tests (oxidative burst test, chemotaxis assay), endoscopy and imaging (evaluation of inflammatory bowel disease), and SLC37A4 gene analysis. When GSD Ib is suspected, gastrointestinal evaluation such as upper gastrointestinal contrast study, colonoscopy, and small-bowel endoscopy is performed to check for ulcers, strictures, and fistulas.


10. Treatment

Treatment of von Gierke disease centers on maintaining normal blood glucose and correcting metabolic abnormalities, and dietary therapy is the basic treatment. To date there is no enzyme replacement therapy (ERT) or approved gene therapy, and dietary management and symptomatic treatment are central.

Dietary therapy — uncooked cornstarch (UCCS): The most essential treatment. Uncooked cornstarch is digested and absorbed slowly in the gastrointestinal tract and releases glucose gradually (very low glycemic index), preventing fasting hypoglycemia. It can be used from 1 year of age, and 1.75-2.5 g/kg of starch mixed with water is given every 4-6 hours. Waking at night to give it, or continuous infusion through a gastric tube, is used. Extended-release cornstarch (Glycosade) acts for about 6-8 hours and can reduce the number of nighttime doses. All monosaccharides and disaccharides (glucose, fructose, sucrose, galactose, lactose) should be avoided (they are converted to G6P and promote accumulation or promote lactate production), and a diet based on complex carbohydrates is recommended. For infants, continuous gastric tube feeding (continuous overnight glucose infusion) is used instead of uncooked cornstarch.

Treatment of hyperuricemia: Uric acid production is suppressed with allopurinol (a xanthine oxidase inhibitor). When a gout attack or nephrolithiasis occurs, treatment is started immediately, and it is also used prophylactically. Foods high in purines (organ meats, dried fish, shellfish) are restricted in the diet.

Treatment of hyperlipidemia: Reducing triglycerides by dietary control is first-line treatment, but fibrates or omega-3 fatty acids are added when needed. Improved maintenance of blood glucose is the most effective treatment of hyperlipidemia. When hyperlipidemia is severe, fat intake is also restricted to prevent pancreatitis.

Renal protection: In addition to lowering uric acid, ACE inhibitors (e.g., enalapril) or ARBs are given early to reduce glomerular hypertension and suppress progression of proteinuria. When glomerulosclerosis and tubular dysfunction are confirmed, consult nephrology.

Neutropenia in GSD Ib — G-CSF: Granulocyte colony-stimulating factor (G-CSF, filgrastim) is given by subcutaneous injection to maintain ANC at a safe level (1,000/μL or higher). G-CSF administration reduces the frequency of infections and improves oral and gastrointestinal ulcers. However, the risk of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) has been reported with long-term G-CSF use, so regular blood tests and bone marrow examination follow-up are needed. Clinical reports are accumulating that the SGLT2 inhibitor empagliflozin improves neutropenia and gastrointestinal symptoms in GSD Ib, and an effect of reducing the G-CSF requirement has also been reported.

Management of hepatic adenoma (HCA): Liver MRI is performed regularly (once or twice a year) to monitor HCA. Surgical resection is considered for diameter of 5 cm or more, rapid growth, signs of hemorrhage, or suspected malignant transformation on imaging. Shrinkage of HCA with optimization of dietary therapy has also been reported. Liver transplantation has been performed for metabolic correction and curative treatment of HCA in some cases, but it is not standard treatment.

Emergency management: When acute hypoglycemia occurs, blood glucose is maintained at 70-100 mg/dL with intravenous glucose infusion (10% glucose, 8-10 mg/kg/min). Before and after surgery and procedures, the glucose infusion rate is increased and fasting time is minimized. All patients and caregivers should receive training in emergency hypoglycemia management (glucose gel, glucose infusion through a gastric tube).

Gene therapy: In preclinical animal models (mice, dogs), AAV2/8- or AAV9-based G6PC gene delivery succeeded in biochemical and histological correction. AAV gene therapy clinical trials targeting human GSD Ia are currently under way (e.g., UX701, DTX401), and improved maintenance of blood glucose and reduced cornstarch doses have been reported in some. Gene therapy for GSD Ib is also at the research stage.


11. Prognosis

Before dietary therapy was established, most patients with von Gierke disease died in infancy or childhood from severe hypoglycemic complications or infection. Now, with dietary management centered on uncooked cornstarch therapy and symptomatic treatment, survival into adulthood is common, and normal growth, development, schooling, and social participation are possible. However, long-term complications remain a major cause of morbidity and mortality.

Hepatic adenoma (HCA) and malignant transformation: In the long term, HCA develops in about 50-75% of treated GSD Ia patients, and some of these transform into hepatocellular carcinoma (HCC). Hemorrhage within an HCA is an emergency that causes acute abdominal pain and hypotension. Regular liver MRI follow-up from the 20s-30s onward is essential for prognosis management.

Decreased renal function: In the long term, glomerulosclerosis due to uric acid accumulation, chronic hypoglycemia, and glomerular hypertension progresses, and renal function can decline. Cases requiring dialysis or kidney transplantation after middle age have been reported. Early use of ACE inhibitors is important for renal protection.

Osteoporosis and fractures: The acidic environment from chronic lactic acidosis promotes calcium loss and decreases bone density. Regular bone density measurement using DEXA scan and vitamin D and calcium supplementation are needed.

Gout and nephrolithiasis: Allopurinol treatment is effective, but with nonadherence to treatment or poor metabolic control, gouty arthritis and uric acid nephrolithiasis occur.

Additional complications of GSD Ib: Risk of MDS/AML due to long-term G-CSF treatment, progression of inflammatory bowel disease (strictures, fistulas, need for surgery), autoimmune thyroid disease, and so on have been reported. Recent use of SGLT2 inhibitors has improved neutropenia and gastrointestinal symptoms, and a decreased G-CSF requirement has been reported in some patients, so improved prognosis is expected.

Quality of life: Dietary restrictions (complete exclusion of monosaccharides, regular cornstarch intake, nocturnal gastric tube use, etc.) place a heavy burden on patients and families. Psychological support, dietitian counseling, and participation in patient support groups help maintain quality of life.


12. Prevention

Primary prevention of von Gierke disease is achieved through genetic counseling and genetic testing. Parents who have had a child with GSD I have a 25% recurrence risk in the next pregnancy, so they should be given the options of prenatal diagnosis (chorionic villus sampling or amniocentesis, at 11-14 weeks or 15-20 weeks of pregnancy) and preimplantation genetic testing (PGT) through genetic counseling. Family testing of siblings who may be carriers is also offered through counseling.

Prevention of hypoglycemic emergencies: All patients and caregivers should be familiar with emergency management of hypoglycemia (keeping glucose gel on hand for emergencies, in-hospital glucose infusion when oral intake is not possible). It is important to educate teachers and school nurses at schools and childcare facilities about the patient's condition and emergency management. When fasting is required before surgery or tests, the glucose maintenance protocol must be discussed with the treating medical team in advance. Wearing a Medical Alert ID is recommended for all patients.

Diet education and nutritional management: Education on thorough avoidance of foods containing simple sugars (glucose, fructose, sucrose, lactose, galactose) is provided. Fruit juice, honey, candy, sweet drinks, and dairy products (containing lactose) are major causes of metabolic deterioration. Regular dietitian counseling optimizes the balance between growth and metabolic control.

Regular monitoring: Regular follow-up of blood glucose, lactate, uric acid, triglycerides, renal function, and liver function, liver ultrasound or MRI every 6 months to 1 year, bone density measurement (DEXA, every 2-3 years), and, in GSD Ib, comprehensive multidisciplinary follow-up including ANC and gastrointestinal evaluation are key to early detection and prevention of complications. A multidisciplinary team approach involving metabolic specialists, dietitians, genetic counselors, nephrology, gastroenterology, and surgery is recommended.


13. References

  1. Bhattacharya K. Dietary dilemmas in the management of glycogen storage disease type I. J Inherit Metab Dis. 2011;34(3):621-629. DOI: 10.1007/s10545-010-9248-2. PMID: 21229309.
  2. Rake JP, Visser G, Labrune P, et al. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr. 2002;161 Suppl 1:S20-34. DOI: 10.1007/s00431-002-1010-0. PMID: 12373578.
  3. Kishnani PS, Austin SL, Abdenur JE, et al. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet Med. 2014;16(11):e1. DOI: 10.1038/gim.2014.128. PMID: 25356975.
  4. Chou JY, Matern D, Mansfield BC, Chen YT. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Curr Mol Med. 2002;2(2):121-143. DOI: 10.2174/1566524024605798. PMID: 11949934.
  5. Melis D, Pivonello R, Parenti G, et al. Increased prevalence of thyroid autoimmunity and hypothyroidism in patients with glycogen storage disease type I. J Pediatr. 2007;150(3):300-305. DOI: 10.1016/j.jpeds.2006.11.041. PMID: 17307552.
  6. Visser G, Rake JP, Fernandes J, et al. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I. J Pediatr. 2000;137(2):187-191. DOI: 10.1067/mpd.2000.105232. PMID: 10931411.
  7. Keilmann A, Bhatt A, Bhatt H. Glycogen storage disease type Ib and inflammatory bowel disease: a systematic review. Orphanet J Rare Dis. 2020;15(1):283. DOI: 10.1186/s13023-020-01560-x. PMID: 33023650.
  8. Kim SY, Weinstein DA. Glycogen storage disease type Ib: update on management with empagliflozin and new genetic findings. J Inherit Metab Dis. 2022;45(2):235-247. DOI: 10.1002/jimd.12457. PMID: 34882827.
  9. Lee PJ, Celermajer DS, Robinson J, et al. Hyperlipidaemia does not impair vascular endothelial function in glycogen storage disease type 1a. Atherosclerosis. 1994;110(1):95-100. DOI: 10.1016/0021-9150(94)90245-3. PMID: 7945574.
  10. Dagli AI, Zori RT, McCune H, et al. Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet. J Inherit Metab Dis. 2009;32 Suppl 1:S103-108. DOI: 10.1007/s10545-009-1088-x. PMID: 19308665.